Hubei Provincial Center for Disease Control and Prevention
23
1
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 23 trials
100.0%
+13.5% vs industry average
61%
14 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (23)
the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
Role: collaborator
Safety Study of Quadrivalent Subunit Influenza Vaccine in People Aged 3 Years and Older
Role: collaborator
A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10-60 Years
Role: collaborator
Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)
Role: collaborator
Prospective Cohort of Integrated Traditional Chinese and Western Medicine in China
Role: collaborator
Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
Role: collaborator
Phase II/III of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Healthy Children Aged 5-11
Role: collaborator
Phase II of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants
Role: collaborator
The Phase IVb of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Children
Role: collaborator
A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)
Role: collaborator
Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above (6 Months After Two Doses)
Role: collaborator
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPD
Role: collaborator
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged ≥18 Years With HIV Infected
Role: collaborator
Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4
Role: collaborator
Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults
Role: collaborator
Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71
Role: collaborator
Evaluation of Safety and Immunogenicity of Combined Immunization of sIPV, DTaP and HepA
Role: collaborator
To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV
Role: collaborator
Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of sIPV and DTaP
Role: collaborator
The Phase IVc of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell)
Role: collaborator